EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

320 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2021-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Varenicline is the most effective smoking cessation therapy available. Nevertheless, most smokers using varenicline relapse within the first few months after quitting. Varenicline is hypothesized to help smokers to quit in part by reducing the reinforcing effects of smoking during the standard 1-week pre-quitting treatment phase. Learning theory and previous human and animal research support the hypothesis that a longer period of varenicline treatment prior to the target quit date (TQD) will lead to greater reductions in smoking before quitting, and higher long-term cessation rates, compared to standard varenicline treatment. Building on promising preliminary clinical data, the study tests these hypotheses with a full-scale randomized clinical trial (RCT). 320 treatment-seeking smokers will be randomized to a standard run-in group (3 weeks of placebo, followed by the standard 1 week of pre-TQD varenicline) or an extended run-in group (4 weeks of pre-TQD varenicline). Both groups will receive brief individual cessation counseling and 11 weeks of post-TQD varenicline. The primary outcome measure will be bio-verified continuous abstinence at end-of-treatment (weeks 8-11 post-quit; cessation at 26-weeks post TQD will also be examined. Hypothesized mediating mechanisms (e.g., smoking reinforcement) will be evaluated by behavioral, physiological, and subjective measures assessed both in the lab and using real-world, real-time electronic momentary assessments (EMA). The investigators predict that long-term, bio-verified smoking cessation will be improved among the extended run-in group compared to the standard run-in group. The investigators further predict the improved clinical outcomes with extended run-in varenicline will be explained (or mediated) by greater pre-quit reductions in smoking reinforcement among the extended run-in group compared to the standard run-in group. The significance of this work is clear: The project aims to make best available treatment for smoking cessation even better, using a method that is ripe for dissemination and an approach that will elucidate critical mechanisms to target in the next generation of treatment enhancement.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Varenicline-Aided Cigarette Reduction in Smokers Not Ready to Quit

NCT01308736

Tobacco Use Disorder

COMPLETED NA

A Trial of Varenicline for E-cigarette Cessation

NCT07040566

E-cigarette Use Vaping Nicotine Dependence

RECRUITING PHASE2

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

NCT06966362

Veterans Tobacco Use Disorder Cigarette Smoking +1 more

NOT_YET_RECRUITING PHASE4

Concurrent Bupropion / Varenicline for Smoking Cessation

NCT01303861

Nicotine Dependence

COMPLETED PHASE3

Varenicline for Treatment of E-cigarette Dependence

NCT05541497

Smoking Cessation

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extended Run-In

\*\* 4 weeks of varenicline prior to the target quit date (TQD) \*\*

\+ 11 weeks of post-TQD varenicline

Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.

Brief individual counseling at clinic visits

Group Type EXPERIMENTAL

Varenicline

Intervention Type DRUG

oral varenicline tablets

Brief smoking cessation counseling

Intervention Type BEHAVIORAL

\~10-minute individual counseling at each of 6 clinic visits

Standard Run-In

\*\* 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) \*\*

\+ 11 weeks of post-TQD varenicline

Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.

Brief individual counseling at clinic visits

Group Type ACTIVE_COMPARATOR

Varenicline

Intervention Type DRUG

oral varenicline tablets

Brief smoking cessation counseling

Intervention Type BEHAVIORAL

\~10-minute individual counseling at each of 6 clinic visits

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Varenicline

oral varenicline tablets

Intervention Type DRUG

Brief smoking cessation counseling

\~10-minute individual counseling at each of 6 clinic visits

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chantix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Smoking at least 10 cigarettes per day (CPD) for the past 6 months and expired-air carbon monoxide (CO) \>7 at intake. NOTE: To reduce exclusion of Black participants, the CPD criterion was reduced to 5 and the carbon monoxide criterion was eliminated in November, 2019.
* At least moderately motivated to quit smoking and intention to make a quit attempt with varenicline 1 month after treatment begins.
* Planning to remain in western New York (NY) during the study period
* Willing to use varenicline and to refrain from other cessation treatments and tobacco products during the study period.
* English speaker
* To be intent-to-treat (ITT), the participant must complete Lab Visit 1 and meet minimal completion rate for real-world (EMA) assessments.

Exclusion Criteria

* Use of other tobacco products, including e-cigarettes, in past 7 days
* Use of smoking cessation medication, including nicotine replacement therapy, in the past 14 days
* Prior allergy/hypersensitivity to varenicline
* Pregnant or breast-feeding
* Substance use:

* Alcohol: AUDIT score \> 15 at intake, suggestive of alcohol dependence and warranting treatment; for those with scores between 8 and 15, the investigators will advise reducing drinking).
* Medical treatment for substance use (SU) in past 3 months, including Suboxone (buprenorphine) and methadone (at phone screen)
* Using a combination of the National Institute on Drug Abuse (NIDA) modified ASSIST (4-26 = moderate risk; 27+ = high risk) and urine toxicology screen (both at intake):

* Cannabis: ASSIST=27+ (tox screen not used)
* Cocaine: ASSIST=7+ OR positive tox screen
* Methamphetamine: ASSIST=7+ OR positive tox screen
* Inhalants, hallucinogens, sedatives, or sleeping pills: ASSIST score = 7+
* Prescription stimulants: With prescription, ASSIST 27+; Without prescription, ASSIST 7+
* Opioids: With prescription, ASSIST 27+ (note ineligible if prescription is for buprenorphine or methadone); Without prescription, ASSIST 7+ OR positive tox screen

(Note: ASSIST 4+ modified to 7+ in 2018 to avoid excluding people with past SU problems. clinicaltrials.gov edited 12/18/18)

* Psychiatric:

* Antipsychotic medications
* Lifetime history of schizophrenia or bipolar disorder
* Evidence of current major depression (per Patient Health Questionnaire (PHQ-9) at intake
* Past 10 years suicidal ideation (SI) / behavior. At intake, all of the following are exclusionary on the baseline Columbia-Suicide Severity Rating Scale (Posner et al., 2008): SI without intent (C-SSRS #1, #2, or #3), if any intensity rating (Frequency, Duration, Controllability, Deterrents, or Reasons for Ideation) is \> 2; SI with intent (C-SSRS #4, or #5), regardless of intensity ratings; Suicidal Behavior (any suicide attempt, interrupted attempt, aborted attempt, or suicide preparatory acts or behavior on the C-SSRS).
* Any medical condition, illness, disorder or concomitant medication that compromises participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
* Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes